9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one

LGD-3303 is used in methods reducing mammographic breast density and/or breast cancer risk comprising the administration of an effective administration of an androgenic agent and an effective amt. of an aromatase inhibitor. LGD-3303 is also used in combination with anti-TWEAK antibodies for treating muscle atrophy.

LGD-3303 is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects.It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.